Kansas Attorney General Kris Kobach announced a nearly $720 million nationwide settlement with eight pharmaceutical companies accused of fueling the opioid crisis through the production of addictive painkillers.
Kansas will receive approximately $5.7 million from the settlement. Some companies will also provide free pharmaceutical products or offer cash in lieu of those products.
Seven of the companies (excluding Indivior) are now banned from marketing opioids, producing high-dose pills (over 40 mg of oxycodone), and must implement systems to monitor suspicious orders.
Indivior agreed to stop making or selling opioid products for the next 10 years but may continue offering medications for opioid addiction treatment.
The eight companies and their settlement amounts include:
Mylan (Viatris): $284.4M over 9 years
Hikma: $95.8M over 1–4 years
Amneal: $71.8M over 10 years
Apotex: $63.7M (single payment)
Indivior: $38M over 4 years
Sun: $31M over 1–4 years
Alvogen: $18.7M (single payment)
Zydus: $14.9M (single payment)
